Moneycontrol PRO
HomeNewsIndraprasthamedicalcorporation

Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

Jump to
  • Buy Indraprastha Medical; sell Indo Count, Cairn India: Gujral

    Ashwani Gujral of ashwanigujral.com recommends buying Indraprastha Medical and advises selling Indo Count Industries and Cairn India.

  • Bull's Eye: Buy DLF, Havells, LIC Housing, JK Tyre, TVS Motor

    Bull's Eye: Buy DLF, Havells, LIC Housing, JK Tyre, TVS Motor

    CA Rudramurthy BV of Vachana Investments is of the view that one may buy Aurobindo Pharma with a target of Rs 780.

  • Bull's Eye: Buy PFC, JSPL; sell Ceat, Bata, BEL

    Bull's Eye: Buy PFC, JSPL; sell Ceat, Bata, BEL

    Manish Sharma of Derivative Trading Research recommends selling Ceat with a target of Rs 970 and Amara Raja with a target of Rs 840.

  • Bull's Eye: Buy Biocon, Voltas, sell BoI, Crompton Greaves

    Bull's Eye: Buy Biocon, Voltas, sell BoI, Crompton Greaves

    Sharmila Joshi, Market Expert advises buying Biocon with a target of Rs 478.

  • Indraprastha Medical may move to Rs 40: SP Tulsian

    Indraprastha Medical may move to Rs 40: SP Tulsian

    SP Tulsian of sptulsian.com feels that Indraprastha Medical Corporation can move to about Rs 40 maybe in six months. "It has 700 beds hospital in Delhi, which is one of the largest hospitals in the country and they have the capacity to expand to 1,000 beds as well," he adds.

  • Multibagger Picks: Torrent Pharma, Indraprastha Medical

    Multibagger Picks: Torrent Pharma, Indraprastha Medical

    SP Tulsian of sptulsian.com asks traders to keep a view of about six months and look for a target of Rs 500 on Torrent Pharmaceuticals. He expects Indraprastha Medical Corporation, which is now ruling at around Rs 33, to move to Rs 40 maybe in six months or so.

  • Indraprastha Medical can move to Rs 50: SP Tulsian

    Indraprastha Medical can move to Rs 50: SP Tulsian

    Indraprastha Medical can move to Rs 50 in next twelve months, says SP Tulsian, sptulsian.com.

  • Hold Indraprastha Medical: Aashish Tater

    Hold Indraprastha Medical: Aashish Tater

    Hold Indraprastha Medical Corporation for long term, says Aashish Tater, Head of Research, Fort Share Broking.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347